TBPH — Theravance Biopharma Balance Sheet
0.000.00%
- $487.51m
- $429.50m
- $64.38m
- 34
- 21
- 71
- 37
Annual balance sheet for Theravance Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 293 | 173 | 327 | 102 | 88.3 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 69.7 | 57.6 | 16.8 | 17.5 | 68.4 |
Prepaid Expenses | |||||
Total Current Assets | 393 | 250 | 353 | 134 | 161 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 59.7 | 53.3 | 52 | 45.4 | 35.8 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 469 | 375 | 607 | 382 | 354 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 124 | 58.6 | 28.7 | 24.8 | 32.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 773 | 713 | 166 | 169 | 179 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -304 | -339 | 442 | 213 | 176 |
Total Liabilities & Shareholders' Equity | 469 | 375 | 607 | 382 | 354 |
Total Common Shares Outstanding |